drugset

drugset / Trial / NCT04834128

A Phase II Safety and Tolerability Study of TCB008 in Patients With COVID-19

NCT04834128 ↗

Phase 2 Withdrawn TC Biopharm

NaSingle-groupOpen-labelTreatment

Summary

A Phase II safety and tolerability study of expanded gamma delta T cell lymphocytes (TCB008) in patients diagnosed with COVID-19.

Timeline

Start: 2021-12-13
Primary completion: 2022-04-13
Completion: 2022-04-13

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TCB008	Cell therapy	—	Intravenous

Indications